Chronic obstructive pulmonary disease (COPD) describes a predominantly smokinginduced small airway and/or emphysematous disease associated with airflow limitation. Considered progressive, irreversible, and responsible for substantial morbidity and mortality worldwide, COPD remains the subject of vigorous study, and advances made during 2016 are already reflected in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 guidelines (1) . Researchers continue to explore strategies, pharmacological or otherwise, to improve the lives of those who have developed this condition; and it is hoped, by improving phenotyping of this heterogeneous disease, that we might ultimately deliver personalized medicine. Debate remains over how to identify undiagnosed COPD in individuals who would benefit from intervention, while avoiding overdiagnosis, and these controversies perhaps highlight shortcomings in accepted disease definitions. Not unrelatedly, renewed interest has emerged in explaining why some individuals develop COPD and identifying the formative stages of COPD development.
Therapy
A series of studies have been published during 2016 exploring how we might improve treatment of those who have developed COPD.
Therapy for Frequent Exacerbators
Although the GOLD guidelines advocate escalation and deescalation of therapy (1) , few studies are available demonstrating the impact of this approach. The effect of stepping up from twice daily longacting b-agonist (LABA)-inhaled corticosteroid (ICS) (formoterol fumarate and beclomethasone dipropionate) to a LABA-long-acting muscarinic antagonist (LAMA)-ICS single-combination inhaler (formoterol fumarate, glycopyrronium bromide, and beclomethasone dipropionate) was tested within the TRILOGY trial (2) . This double-blind randomized controlled trial studied 1,368 patients with severe to very severe COPD, a moderate-severe exacerbation within the preceding 12 months, and chronic respiratory symptoms. Stepping up to triple therapy for 1 year improved spirometric readings and produced a 23% lower exacerbation rate without a significance increase in adverse events. Unfortunately, this study was not enriched for exacerbations and the low exacerbation rate within this study makes interpretation more difficult.
An alternative approach to those at high risk of COPD exacerbation was tested by the FLAME study, which compared combined twice daily LABA-ICS (salmeterol-fluticasone) with oncedaily LABA-LAMA (indacaterolglycopyrronium) (3) . FLAME studied individuals with COPD and FEV 1 less than 60% predicted who had received treatment for an exacerbation in the preceding year and demonstrated LABA-LAMA to be superior to LABA-ICS in reducing the exacerbation rate. Within the LABA-LAMA group, the overall exacerbation rate was 11% lower, with a 17% reduction in moderate/severe exacerbations, defined as exacerbations requiring the use of health care services. LABA-LAMA therapy was also associated with greater improvements in both FEV 1 and health status (greater decreases in St. George's Respiratory Questionnaire score) but lower rates of pneumonia, without any difference in mortality These findings suggest that dual bronchodilator therapy among high-risk patients with COPD is safe and effective at reducing the exacerbation rate and improving both lung function and health status.
Studies are now required to compare LABA-LAMA with LABA-LAMA-ICS to determine whether triple therapy adds any incremental benefit over dual bronchodilator therapy (4) . Future studies recruiting patients with a wider range of comorbidities may also prove useful in determining how treatment guidelines may be improved (5) .
The applicability to everyday practice of clinical trials, which by design usually include highly selected patient groups, is frequently questioned. The Salford Lung Study aimed to address this issue by evaluating the effectiveness and safety of combination once-daily LABA-ICS (vilanterol and fluticasone furoate) versus usual care within a "real-world population" across 75 family practices (6) . By totally avoiding smoking or spirometric inclusion criteria, and instead basing enrollment on a general practitioner-documented COPD exacerbation within the previous 3 years together with long-term maintenance inhaler therapy prescription, the authors reported a pragmatic approach to studying patients to whom the findings from COPD trials are often applied (7) . Indeed, 50% of the study sample was previously receiving triple therapy despite preserved lung function. The study reported an 8.4% lower moderate-to-severe exacerbation rate in those using combined LABA-ICS rather than usual care (P = 0.02) without an increase in serious adverse events. Subpopulation analysis also showed that this change was driven by patients previously treated with ICS, LABA-ICS, and LAMA-ICS therapy. Although the open label nature of the study may have led to bias, perhaps responsible for the high number of treatment switches, the innovative design arguably delivers a more "real world" study providing safety data complementary to those from more traditionally designed clinical trials.
Conversely, the RE 2 SPOND (Roflumilast Effect on Exacerbations in Patients on Dual [LABA-ICS] Therapy) trial illustrates how recruiting specific patient subgroups may reveal treatments particularly beneficial to those individuals. This study investigated the effect on exacerbation rate of adding roflumilast to standard COPD care (8) , enrolling patients with at least severe-grade COPD, chronic bronchitis, and two or more exacerbations within the preceding year. Roflumilast is a phosphodiesterase-4 inhibitor, known to reduce both neutrophilic and eosinophilic inflammation, which is already licensed for use in patients with COPD with chronic bronchitis and FEV 1 less than 50% predicted.
Overall, this study found that roflumilast had no significant impact on exacerbation rate, and the trial therefore failed to meet its predetermined primary end point. However, post hoc analysis did show a 39% reduction in exacerbation frequency with roflumilast use, relative to placebo, among those who had experienced three or more exacerbation within the previous year (P = 0.03) (Figure 1 ), supporting the results of the earlier published REACT (Roflumilast and Exacerbations in Patients Receiving Appropriate Combination Therapy) study (8) . Those with frequent exacerbations, who perhaps should be considered "superexacerbators" (9), may therefore obtain particular benefit, perhaps because they have enhanced airway inflammation that responds to roflumilast (9) . Better understanding the pathophysiological mechanisms underlying the superexacerbator state together with studies of therapy among these superexacerbators, coupled with rigorous exacerbation recording, may reveal not only therapeutic benefits for this subgroup but ways to substantially lessen the overall burden of COPD exacerbations on health care services. Further studies of triple therapy are expected to be reported in the near future.
Drug Adherence and Health Care Delivery
Adherence to prescribed inhaler therapy was examined in a prospective observational study by Sulaiman and colleagues (10) using an electronic audio recording device to quantify frequency and technique of inhaler use. Worryingly, this small study of 244 patients recently discharged from hospital found a mean actual adherence of only 22.6%, with only 6% using maintenance inhaler therapy regularly and with correct technique greater than 80% of the time. These data highlight a major obstacle to delivering treatment benefits to patients.
Simplifying treatment regimens, such as using once-daily maintenance inhaler therapies as investigated within the FLAME (3) and Salford (7) studies, may improve adherence. However, the challenges described by Sulaiman and colleagues (10) are unlikely to be solved purely through novel inhaler formulations, perhaps instead requiring tailored health care provision to encourage long-term behavioral change.
The effect of comprehensive health coaching on readmissions was examined by Benzo and colleagues within a randomized 1-year-long trial. Coaching was found both to improve health status and reduce hospital admission for up to 6 months (11), perhaps explainable through PULMONARY, SLEEP, AND CRITICAL CARE UPDATE improved motivation, behavior change, and enhanced medication adherence. Instead of being seen as a treatment itself, coaching and similar programs might be considered as the process or the manner in which long-term health care is provided (12) and as another component of personalized medicine. Pulmonary rehabilitation has features in common with health coaching and within a multicenter randomized control trial of 143 patients with moderate to severe COPD, Güel and colleagues have shown that participating in a 3-year maintenance program after an initial course of rehabilitation results in better maintenance of functional improvement and patient-reported outcomes relative to a control group (13) . Modifying behavior or lifestyle is notoriously difficult, but these studies suggest that personalized strategies assist in this challenge and should be better incorporated into everyday patient care.
Long-Term Oxygen Therapy
Long-term oxygen therapy (LTOT) improves survival among those with chronic respiratory failure and severe resting hypoxemia, but a landmark study in 2016 showed that LTOT among those with more moderate hypoxemia does not alter mortality, time to hospitalization, or other patient-centered outcomes (14) . This large study randomized 738 patients with COPD and mild-to-moderate hypoxemia at rest or during a 6-minute-walk test to receive either LTOT or no LTOT. The lack of clinical effectiveness supports guideline advice that LTOT should not be routinely provided to those with stable COPD and moderate hypoxemia (1, 15) .
Emphysema and Endobronchial Valves
Endobronchial valves are already a therapeutic option for those with heterogeneous emphysema, but their use may also be beneficial to those with homogeneous emphysema. The IMPACT (Improving Patient Outcomes by Selective Implantation of the Zephyr EBV) study randomized 93 patients with homogeneous emphysema, without collateral ventilation, to receive standard care versus unilateral lobar occlusion targeting the worse affected lobe (16) . Although the 17% difference in FEV 1 achieved between groups is smaller relative to interventions in heterogeneous emphysema, this was accompanied by improvements in exercise tolerance and quality of life scores ( Figure 2 ). Endobronchial valve insertion is not without risk (procedure-related pneumothoraces occurred in 26% of the study sample), and careful patient selection with multidisciplinary input will remain essential to extending this therapy to this wider population (17) .
Phenotyping and Biomarkers
Several of the therapies already discussed target specific clinical COPD phenotypes, such as the frequent exacerbator, those with chronic bronchitis, and those with significant emphysema. Efforts continue to enhance phenotypic characterization and the quantification of underlying variability through biomarkers, aiming to predict therapy response and thereby facilitate precision medicine (18) .
Asthma-COPD Overlap
Given the high prevalence of asthma-like features, such as bronchodilator reversibility, atopy and eosinophilia among those with COPD, and the historical failure to include such individuals in either asthma or COPD trials, an asthma-like COPD phenotype remains a key area of active research. However, defining the asthma-COPD overlap syndrome (ACOS) remains controversial, especially without 
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a unifying targetable molecular pathway or understanding how such overlap impacts on the clinical disease course (19, 20) .
The influence of ACOS-defining criteria on prognosis was highlighted by Suzuki and colleagues, who investigated how asthma-like features influenced the clinical course of patients with COPD after excluding those with physician-diagnosed asthma (21) . Within this 10-year Japanese multicenter observational study, neither bronchodilator reversibility, nor blood eosinophilia, nor atopy was associated with worse clinical outcome. Instead, and perhaps surprisingly, subjects with blood eosinophilia were associated with slower annual FEV 1 decline than those without eosinophilia, and those with two or more asthma-like features had significantly lower 10-year all-cause mortality than those with one or no asthma-like features. Similarly, a prospective Spanish study found that 15% of the 831 patients with COPD who met ACOS criteria had lower 1-year mortality than those without ACOS (22) . Better responsiveness to already implemented therapies might explain these findings (19), although proving this by observational studies of patients with COPD, often already established on therapy, will be challenging.
Eosinophils as a Biomarker
Eosinophilic inflammation is central to asthma phenotyping, yet the role of peripheral blood eosinophils as a biomarker in COPD or ACOS is less clear. Using the population-based Copenhagen General Population Study, Vedel-Krogh and colleagues showed that an increased baseline blood eosinophil level among those with COPD was associated with greater risk of exacerbations (23) (Figure 3 ). Receiver operating characteristic curves determined the optimal cutoff point as 0.34 3 10 9 cells per liter, above which eosinophilia was associated with a 1.76-fold increased risk of severe exacerbations (23) , suggesting that absolute rather than relative blood eosinophil count may be a more robust predicator of exacerbation frequency (24) . It remains to be seen, however, whether this relationship indicates a susceptibility to exacerbations, perhaps driven by eosinophilia, or whether eosinophilia represents a residual marker of preceding exacerbations or viral infections.
Pavord and colleagues investigated how peripheral eosinophilia might predict how the initiation of combined LABA-ICS (salmeterol-fluticasone propionate) influences the COPD exacerbation rate (25) . This retrospective analysis of data from three randomized trials-combined therapy versus tiotropium (INSPIRE), combined therapy versus monoconstituents versus placebo (TRISTAN), and combined therapy versus fluticasone propionate versus placebo (SCO3002)-found blood eosinophilia of 2% or greater to be associated with a subsequent reduction in exacerbation frequency within two of the three studies.
In addition, a pooled meta-analysis including 10,861 patients, enrolled within 10 randomized controlled trials involving an inhaled corticosteroid arm, suggests Figure 3 . Data from the Copenhagen General Population Study. Shown is the risk of severe and moderate exacerbations in individuals with chronic obstructive pulmonary disease (COPD) and individuals with clinical COPD, using the cut points for blood eosinophils of 0.34 3 10 9 cells per liter and 3.3%. N represents the number of individuals, and events indicates the total number of events. Incidence rate ratios (IRRs) are given with 95% confidence intervals (CIs). Models were multivariable adjusted for age, sex, FEV 1 as a percentage of predicted value, smoking status, cumulative smoking, education, and body mass index. Reproduced from Reference 23.
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those with blood eosinophil counts less than 2% more commonly developed pneumonia, perhaps indicating an impaired resilience to infection (26) . Likewise, among those using inhaled corticosteroids, the authors found a plausible, yet nonsignificant, trend toward pneumonia developing more commonly if eosinophils count was less than 2% rather than greater than 2%, reinforcing a potential role for blood eosinophils in guiding long-term therapy. However, although these data suggest eosinophil levels predict a better response to corticosteroid, it does not necessarily follow that this is the optimal therapy. The prospectively designed FLAME study found that in both those with eosinophils less than 2% and those with eosinophils at 2% or greater, exacerbations were lower in the LAMA-LABA arm than in the LABA-ICS arm (3) . Data from the WISDOM study also suggest that dual bronchodilator therapy may disrupt the usefulness of a 2% peripheral eosinophil cutoff in predicting how ICS may reduce exacerbation rate (27) . WISDOM included patients with severe or very severe COPD, commenced LAMA-LABA-ICS, and then compared exacerbation rates after stepping down therapy from LAMA-LABA-ICS to LAMA-LABA versus continuing triple therapy (27) . Although the main findings from this study were published in 2014 (28), a recent post-hoc analysis tested the hypothesis that patients with higher baseline eosinophils would be more likely to "relapse" and experience more frequent exacerbations after ICS withdrawal. However, this analysis found that a treatment-by-subgroup interaction became apparent only when baseline peripheral eosinophilia reached 4% (27) .
Peripheral eosinophilia bears the hallmarks of a promising biomarker to guide ICS use. However, the exacerbation rate can also be reduced through dual bronchodilator therapy, and determining the eosinophil cutoff at which patients using dual bronchodilators will benefit from additional ICS requires prospective studies comparing triple therapy versus dual bronchodilator therapy.
Other Biomarkers
For biomarkers to be useful within the COPD population, they must not only be predictive but their associations should be reproducible across different COPD studies. Keene (29) . After biomarker association with exacerbation risk was adjusted for age, sex, FEV 1 , smoking, health status, and reported gastroesophageal reflux, no biomarker, including eosinophils or fibrinogen, was reproducibly associated with future exacerbation frequency. In contrast, clinical variables (such as prior exacerbation history, dyspnea, spirometry, and gastroesophageal reflux) predicted future exacerbation across both cohorts, and the biomarkers studied added little to such predictions. One explanation for these findings, as the authors highlight, is that exacerbations are etiologically heterogeneous in nature and that seeking a single blood marker, or even a combination of blood markers, to predict such events may be an unrealistic goal.
Although disappointing, this highquality study reinforces the importance of clinical indicators, and with better phenotyping of patients and exacerbations, reproducible biomarker associations may become apparent (24, 29, 30) .
Multimorbidity Vascular Diseases and COPD
A well-documented link exists between lung function impairment and both cardiovascular and cerebrovascular diseases (31, 32) , although the mechanisms underlying this relationship remain unclear.
Within a large population-based prospective study spanning 10 years, Portegies and colleagues found that both ischemic and hemorrhagic strokes more commonly occurred among those with COPD (33) . Adjustment for smoking diminished this relationship (33) , suggesting that part of the reason these respiratory and cardiovascular conditions coexist is because of their shared smoking etiology, although some also argue that pulmonary impairment represents a marker of early life adversity, which predisposes to cardiovascular disease development (34) . Importantly, Portegies and colleagues also found a sixfold higher stroke risk within 7 weeks post-COPD exacerbation onset (33) . Therefore, exacerbation-related systemic inflammation, hypoxia, and ensuing endothelial dysfunction may contribute to vascular reactivity, rupture of atherosclerotic plaques, and stroke development (31) .
Evidence has also emerged suggesting a possible link between peripheral artery disease and emphysema (35) (Figure 4) . The multicenter COSYCONET (COPD and Systemic Consequences-Comorbidities Network) cohort study found that peripheral vascular disease was not only more common among those with COPD, substantially adding to functional impairment, but that its presence was associated with impaired diffusion capacity even after adjustment for multiple confounders (36) . Crucially, within the COSYCONET study peripheral artery disease appeared unrecognized in twothirds of affected patients with COPD (36) . Conversely, the ALICE (Airflow Limitation in Cardiac Diseases in Europe) study found that 30.5% of those with ischemic heart disease also had airflow limitation but that less than one-third of these individuals had received a relevant diagnosis, despite a heavy symptom burden and poorer patient-related outcomes (37) .
The overlapping symptom profiles of these conditions may contribute to the substantial underdiagnosis of COPD among those already diagnosed with vascular disease and vice versa, but this 
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may also reflect superspecialization and an underappreciation of how closely these conditions are related (32) . Although we are not yet in a position to therapeutically target an overarching pulmonary-cardiovascular syndrome, when encountering patients with COPD these data should prompt us to pay attention not only to smoking cessation but other cardiovascular risk factors, such as hypertension and hypercholesterolemia (31) , and consider whether cardiovascular disease might already be present.
Impact of COPD Treatments on the Cardiovascular System
The exclusion of individuals with both COPD and cardiovascular disease from randomized controlled drug trials has left uncertainty regarding the cardiac effects of drugs targeting COPD, especially given the differing pharmacological receptor profiles present across the cardiopulmonary system.
To partly address this knowledge gap, the 3-year multicenter double-blind placebo-controlled SUMMIT (Study to Understand Mortality and Morbidity) enrolled 16,590 patients with symptomatic moderate COPD who reported a history of, or were at increased risk of developing, cardiovascular disease (38) .
The study investigated the mortality effects of once-daily treatment with inhaled fluticasone furoate (100 mg) versus vilanterol (25 mg) versus combination fluticasone furoate (100 mg) and vilanterol (25 mg) versus placebo (38) . The main finding was that neither LABA-ICS nor its constituents improved survival, even among a sample enriched for cardiovascular comorbidities. Despite this negative primary end point, it is perhaps reassuring that neither did these widely used therapies appear to worsen cardiovascular outcomes.
Although no improvement in cardiovascular mortality or events was found by SUMMIT, Stone and colleagues reported that the use of combination fluticasone furoate-vilanterol may favorably alter cardiac function (39) . Using magnetic resonance imaging, this double-blinded placebo-controlled crossover study showed that decreases in residual volume after short-term treatment with combination fluticasone furoate-vilanterol was accompanied by improved cardiac function and increased artery pulsatility (39) . Although small, this is the first well-designed study providing evidence that pharmacologically treating hyperinflation can improve cardiac function, presumably by targeting cardiac underfilling (40) . It remains unclear how long these cardiac effects may last and whether dual bronchodilator therapy could provide even greater benefit (40) . Determining how these reported improvements translate clinically, and which patients might benefit most, may reconcile these findings with those from SUMMIT.
Case Finding and Accurate Diagnosis
COPD frequently remains undiagnosed, suggesting the actual disease burden is considerably greater than recorded. However, it remains unclear how beneficial diagnosing these "missed" individuals would be (41) (42) (43) . An uncomfortable tension exists between ensuring those with clinically relevant COPD are correctly identified and appropriately treated versus overmedicalizing individuals with mildly abnormal spirometric results.
The population-based CanCOLD study found that those with spirometric evidence of COPD but without a physician diagnosis had milder disease, and perhaps relatedly, reported fewer symptoms, better patient-reported outcomes, and fewer exacerbations than individuals who had received a physician diagnosis of COPD (43) . However, when those with undiagnosed COPD developed an exacerbation, there was a significant impact on health care services, events that might be avoided if affected individuals were identified and appropriately treated earlier (41, 43) . Simple questionnaires combined with selective peak flow screening may offer one option for sensitive and specific case-finding methodology within primary care (42) , but wider validation and data regarding both the clinical benefit and the implications of diagnosing these individuals are required.
Expanding knowledge of what constitutes normal versus abnormal spirometric values across different ages and ethnicities is also providing scope to refine the spirometric COPD diagnosis and severity classification criteria (44) . The GOLD guidelines currently promote use of fixed FEV 1 /FVC less than 0.7 and FEV 1 percent predicted criteria, which although useful in many respects, with advancing age may overestimate both airflow limitation presence and predicted FEV 1 (44, 45) . The Global Lung Initiative equations calculate spirometric z scores defining lower limit of normal values as the fifth percentile of distribution and appear to reduce overdiagnosis of airflow limitation among the elderly (45) . Given the aging population, accurate diagnosis among the elderly is essential to avoid rising iatrogenic harm and unnecessary expenditure.
Using COPDGene data, Vaz Fragoso and colleagues have now shown that Global Lung Initiative equation-based severity grading of COPD as mild, moderate, or severe correlates in a graded manner with respiratory-related phenotypes, such as breathlessness, quality of life, exercise performance, emphysema, and gas trapping (46) . Such studies may lead to scientifically based diagnostic and grading, which not only reduces misdiagnosis but is more meaningful in terms of disease burden, offering hope in the quest to identify those in need of our attention.
Shifting Focus toward Disease Development and Early COPD
The controversies regarding those with borderline diagnosable disease perhaps highlight shortcomings regarding a concept of COPD constrained by the historical practice of studying older individuals with already well-established disease, rather than studying how this disease develops. Identifying how COPD develops, and ultimately early COPD, is an increasingly attractive topic, as early disease identification may permit early intervention to prevent progression to more severe disease stages.
Symptomatic Smokers without Airflow Limitation
The inclusion of smokers/ex-smokers both with and without airflow limitation within the large COPDGene and SPIROMICS cohorts has allowed investigators to provide new insights into the presence of pathology and morbidity among those with COPDlike features but without airflow limitation.
Bhatt and coworkers analyzed data from the 1,508 individuals enrolled within the COPDGene study, using parametric response mapping (Figure 5) 
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associations between small-airway disease, emphysema, and FEV 1 decline over 5 years of follow-up (47) . Parametric response mapping matches inspiratory and expiratory computed tomographic scans, together with density thresholds allowing functional smallairway disease to be distinguished from emphysema. Bhatt and colleagues found that among those with GOLD grade 1-4 COPD, both emphysema and small-airway disease was associated with accelerated future FEV 1 decline. However, these investigators also reported that although both emphysema and small-airway disease increase with disease grade, among the GOLD 0 group the presence of small-airway disease, but not emphysema, indicated accelerated FEV 1 decline. This may suggest that small-airway disease precedes emphysema (48) .
Parametric response mapping was also employed by Martinez and colleagues (49) within a cross-sectional analysis of SPIROMICS cohort data. Using this indirect measure of small-airway function, the authors found a roughly 2% increase in functional small-airway abnormality per decade after age 50 years. This was a study of individuals of various ages rather than a study of aging within the same individuals, and therefore these data cannot definitively show disease development with aging. However, this study does illustrate the potential difficulties in distinguishing the development of diseases, such as COPD, from airway abnormalities that accompany advancing age and thereby highlights the need to further refine our COPD diagnostic thresholds.
A second article from the SPIROMICS group this year examined GOLD stage 0 current or ex-smokers (50) and showed that chronic symptoms among smokers without airflow limitation identified a group that experienced exacerbations, had increased airway thickening and diminished FEV 1 and FVC readings, and exhibited lower exercise tolerance (50) . This publication further highlights how current spirometric COPD definitions fail to reflect the spectrum of smoking-associated lung disease (51) . However, this mild-grade disease, identified in a sample of individuals mostly older than 50 years, does not necessarily equate with early-phase COPD, and follow-up studies examining progression to established COPD will be keenly awaited.
The Development of Disease across Life
Two studies published in the Journal in 2016 offer a longer perspective on COPD development. Tagiyeva and colleagues reported data collected from the 239 individuals monitored within the Aberdeen WHEASE cohort recruited at age 10-15 years and followed until age 60-65 years (52) . Within adjusted multivariate analysis, both wheezy bronchitis and childhood asthma were associated with impaired adult lung function in the development of COPD. Although this study contained a low number of smokers, it adds to the growing literature indicating the importance of early life events in the development of adult diseases such as COPD (53) and how physiological "snapshots" during later life insufficiently explain adult disease patterns.
The nationally representative MRC National Survey of Health and Development (NSHD) reported data from almost 2,000 individuals monitored since enrollment at birth in March 1946 (54) . This study showed how the relationship between chronic mucus hypersecretion (CMH), also known as chronic bronchitis, and smoking 
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evolves between age 20 and 64 years and that the longer CMH is present, the greater the FEV 1 lost. CMH presence among smokers escalated between age 36 and 43 years ( Figure 6 ), and identified smokers at higher risk of having COPD in their seventh decade. Therefore, CMH presence during midlife may indicate early-stage COPD development. Unlike many studies, the NSHD highlighted the dynamic course of CMH across life. Although most (60%) of those who developed COPD had experienced a phase of CMH across the study, only one-half of these individuals still reported CMH at age 65 years (55) . Such life-spanning studies can offer precious insights into how disease develops over decades, and by challenging existing assumptions they may reveal new diagnostic, mechanistic, and therapeutic approaches to the condition currently labeled as COPD.
Genetic Predisposition
Although it is widely believed that COPD develops partly as a result of genetic susceptibility, the overall heritability of COPD has been difficult to conclusively prove, aside from those risks associated with alpha-1 antitrypsin deficiency (56) .
Qiao and colleagues explored whether rare genetic variants might partly explain the presence of severe COPD within the Boston EOCOPD (Early-Onset COPD) study by conducting whole-exome sequencing among 347 members. The authors then explored whether candidate variants identified were associated with COPD within the COPDGene cohort (57) . Although novel because it targeted COPD by whole-exome sequencing, this study found only trends of association that were nonsignificant. This might indicate the need for larger studies better powered to detect rare variants, but which might also be capable of investigating interactions between genes and smoking (56) . It is also possible, as the authors point out, that susceptibility to COPD is determined by multiple rather than just a few genes (57) .
A cross-sectional genetic study, published by Kusko and colleagues, was even smaller in size, but this study is also one of the first to use unsupervised network approaches to try to identify common transcriptomic pathways across various lung diseases, in this case COPD and idiopathic pulmonary fibrosis (58) . Using RNA sequencing, these authors showed that the p53/hypoxia pathway was activated within lung tissue taken both from patients with COPD and patients with idiopathic pulmonary fibrosis relative to samples taken from healthy lungs, perhaps suggesting these diseases share a common tissue-remodeling pathway. This study reveals the potential for next-generation sequencing to help identify common disease pathways across traditional disease boundaries (59) . However, given the findings from the longitudinal population studies discussed earlier, it would be surprising if such cross-sectional genetic studies proved able to fully explain COPD heterogeneity. Instead, future studies need to be powered to study interactions between genes and environment.
Furthermore, these relationships need to be explored over extended periods to delineate how genetics, environmental exposures, and the aging process together influence chronic disease development.
Conclusions
This update covers an important, yet small portion of the COPD research published during 2016. Advances have been made regarding how we should use existing therapies, both by identifying recipients who might benefit most and determining how the benefits acquired from therapies might be optimized. The studies discussed also highlight opportunities to tailor COPD therapy to an individual patient by considering their clinical phenotype, the nature of their airway inflammation, and their comorbidities. In addition, the approach by which therapy is delivered can also be personalized to help the individual optimally manage their long-term condition. Although smoking cessation and avoidance remain central to COPD prevention and progression, the lack of therapies capable of modifying established disease remains frustrating. Perhaps by better understanding the mechanisms by which COPD develops and how disease heterogeneity evolves across life we might discover those game-changing therapeutic approaches that have thus far remained elusive. n
